AstraZeneca, Sanofi win FDA advisory committee backing for RSV therapy nirsevimab (AZN)

0


Respiratory Syncytial Virus with lung ct scan aside on light blue background. RSV disease concept

Ildar Imashev/iStock via Getty Images

A U.S. Food and Drug Administration (FDA) advisory committee on Thursday voted in favor to recommend approval of Sanofi (NASDAQ:SNY) and AstraZeneca’s (NASDAQ:AZN) antibody therapy to prevent respiratory syncytial virus (RSV) infection in newborn babies and infants.

The FDA’s Antimicrobial



Source link

Leave A Reply

Your email address will not be published.